Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Leadless pacemaker shown safe in older, sicker patients

Key clinical point: The Micra leadless pacemaker showed safety in an elderly Medicare population with many comorbidities.

Major finding: The 6-month complication rate was 3.3% in Micra recipients and 9.4% in matched historical controls who received transvenous-lead pacemakers.

Study details: Micra CED, with 5,746 Medicare patients who received a leadless pacemaker during 2017-2018, and 9,662 matched Medicare controls who received a transvenous VVI pacemaker.

Disclosures: The study was sponsored by Medtronic, which markets the Micra leadless pacemaker. Dr. Piccini has received honoraria from Medtronic and several other companies.

Citation:

Piccini JP et al. Heart Rhythm 2020, Abstract D-LBCT04-01.